Abstract: Objective To investigate whether intravenous administration nicorandil can protect renal function in ACS patients with type 2 diabetes mellitus after PCI and the possible mechanism. Methods The ACS patients with DM who were selected for PCI were randomly divided into the control group(intravenous hydration treatment)and the observation group(intravenous hydration treatment + intravenous administration nicorandil treatment 0.1 mg/kg·h from 5 h before PCI to 24 h after PCI). All patients underwent blood sampling at 24 h before PCI and 6 h, 24 h, 48 h and 72 h after PCI to detect indicators related to renal function, inflammation and cardiac function. The main endpoint was the incidence of CIN. Results The levels of SCr, β₂-MG and CysC in the observation group at 48 h and 72 h after PCI were lower than those in the control group, the difference was statisticallysignificant(P＜0.05). The eGFR in the observation group at 48 h and 72 h after PCI was significantly higher than that in the control group, and the difference was statistically significant(P＜0.05). The level of hs-CRP, SAA, NLR and NT-ProBNP in the observation group were significantly lower than those in the control group at 24 h after PCI, there was significant difference between two groups(P＜0.05). Conclusion Intravenous administration nicorandil can not reduce the incidence of CIN, but can protect renal function and cardiac function in ACS patients with DM after PCI. The possible mechanism is to inhibit the inflammatory response and increase renal perfusion.

Key words: contrast-induced nephropathy, serum creatinine, cystatin C, nicorandil, acute coronary syndrome, diabetes mellitus, percutaneous coronary intervention